With an aim to focus on the sales and marketing of biotech drugs, oncology as well as plasma products, Intas Biopharmaceuticals Limited (IBPL) has launched three new sales divisions, Track, Aqua and Relay. The sales and marketing of the drugs through Track, Aqua and Relay is aimed to cater to solid tumours, haematology and supportive therapies respectively. The segregation of sales divisions, based on therapeutic segments, is aimed to increase focus and penetration of Oncology products in the domestic market.

Announcing the development, Simon Daniel, chief executive, marketing, IBPL, said, "To give impetus to IBPL's sales activities, the company plans to launch one more new division Bridzge catering to Nephrology / Neurology therapeutic areas in the calendar year. As part of new sales strategy, IBPL has doubled its sales force to allow more focussed approach towards niche therapeutic areas of Oncology. Additionally, new division Aqua will look after sales activity of plasma products namely - Albumin and Globucel - marketed through Celestial Biologicals, associate company of IBPL."

Celestial Biologicals focuses on the manufacturing and marketing of plasma-derived products. Currently Celestial has two products, Albumin and Globucel - in the domestic market and has plans to expand its product portfolio of Coagulation Factors (Factors VIII, IX, and Fibrinogen).

Intas entered the Indian anti-cancer market in the year 1998 with the launch of Novatech division (oncology marketing division). Starting with a product basket of a few oncology products in 1999, today, IBPL can boast of one of the most comprehensive oncology product baskets comprising of 26 products in different dosage forms (capsules, injections, tablets and pre-filled syringes).